Compound Screening & Cellular Response Evaluation Improvements

Posted by Tracy Hendershott on Dec 4, 2018 9:00:00 AM
Tracy Hendershott
Find me on:

Double exposure of chemist doctor hand drawing chemical formulas on virtual board

We would like to congratulate our colleagues at Eurofins DiscoverX for their recent patent application approval for improvements to compound screening and evaluation on cellular responses.

Being the first step of the drug development pathway, high-volume compound screening and patented biomap analysis brings scientific value to our clients within the Eurofins BioPharma Services division. As the largest wholly-owned network of laboratories dedicated to the biopharma development in the world, Eurofins BioPharma Services provides true end-to-end solutions to industry.


For the product development line of research, we start with:

  • Eurofins DiscoverX - Dedicated laboratories in compound identification
  • Product Safety Labs - Qualification of compound in pre-clinical trials
  • Eurofins Amatsi Group - CDMO/Contract Development and Manufacturing 
  • Eurofins Lancaster Labs - Global GMP with capabilities to cover the compound throughout the entire development process

For the clinical analysis line of research, Eurofins BioPharma Services provides:

New call-to-action

Please download our Eurofins BioPharma Services brochure above for greater detail on all our analytical services. We look forward to continuing collaboration on developing life-changing treatments!

 

 

Tags: Compound Screening, Cellular Response, DiscoverX